Vir Biotechnology (VIR) Competitors

Vir Biotechnology (NASDAQ:VIR) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Which has higher earnings and valuation, VIR or ARWR?

Vir Biotechnology has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$74.21M	8.31	-$521.96M	-$4.00	-1.11
Arrowhead Pharmaceuticals	$3.55M	731.41	-$599.49M	-$1.28	-14.67

Is VIR or ARWR more profitable?

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -2,895.94%. Arrowhead Pharmaceuticals' return on equity of -40.91% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-2,895.94%	-50.22%	-40.78%
Arrowhead Pharmaceuticals	N/A	-40.91%	-11.62%

Do analysts prefer VIR or ARWR?

Vir Biotechnology presently has a consensus price target of $30.25, indicating a potential upside of 581.31%. Arrowhead Pharmaceuticals has a consensus price target of $43.14, indicating a potential upside of 129.73%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Arrowhead Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in VIR or ARWR?

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 16.0% of Vir Biotechnology shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, VIR or ARWR?

Vir Biotechnology has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Does the media favor VIR or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than Vir Biotechnology. MarketBeat recorded 25 mentions for Arrowhead Pharmaceuticals and 12 mentions for Vir Biotechnology. Arrowhead Pharmaceuticals' average media sentiment score of 0.44 beat Vir Biotechnology's score of 0.38 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arrowhead Pharmaceuticals beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.